-+ 0.00%
-+ 0.00%
-+ 0.00%

Sanofi Investigational Gene Therapy SAR402663 Wins FDA Fast Track Status To Treat Neovascular Age Related Macular Degeneration

Benzinga·09/11/2025 05:30:58
Listen to the news

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

  • Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degeneration
  • Neovascular or "wet" age-related macular degeneration can lead to significant vision loss and affects more than one million people in the US